{"id":692885,"date":"2022-10-06T08:33:48","date_gmt":"2022-10-06T12:33:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/"},"modified":"2022-10-06T08:33:48","modified_gmt":"2022-10-06T12:33:48","slug":"ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/","title":{"rendered":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MALVERN, Pa., Oct.  06, 2022  (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.<\/p>\n<p>\u201cI look forward to sharing more about our Modifier Gene Therapy platform\u2014a novel approach to treating inherited retinal disease\u2014during the Meeting on the Mesa, and Dr. Hopkins will provide more on COVAXIN\u2122\u2014 a whole-virion inactivated COVID-19 vaccine candidate currently in a Phase 2\/3 immuno-bridging and broadening clinical trial with the U.S. FDA\u2014at the Vaccines Summit,\u201d said Dr. Shankar Musunuri, PhD, MBA, Chairman, CEO &amp; Co-Founder of Ocugen. \u201cIt\u2019s critical that we participate in conversations about the next generation of medicine among our peers and share our contributions to the advancement of vaccines, cell and gene therapy.\u201d<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cAOXp4fRwk7tF_qCSw0VesqWqmb7IBa9kIvSk5S4uh1gY9T8lIRjELeq4HwsnCwoRRF8j4wr6EpJ6bSvW9hBBZ2oJXzjxvau4521zm4XIm6ZW0xZS3sbD3-XhsAhGY-Z1rY9Smci3vQMZpL92pycpg==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>2022 Cell &amp; Gene Meeting on the Mesa<\/strong><br \/>\n        <\/a><br \/>\n        \n      <\/p>\n<p>\n        <strong>Title:<\/strong> Our Commitment to Gene &amp; Cell Therapy<br \/><strong>Presenter:<\/strong> Dr. Shankar Musunuri<br \/><strong>Date:<\/strong> Wednesday, October 12, 2022 <br \/><strong>Time:<\/strong> 2 p.m. PT<br \/><strong>Location<\/strong>: Park Hyatt Aviara, Carlsbad, CA<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IETS7hEjlkbvBuXjEWXSiKpjUFFCMQ3S23gqz1JLhTmLNl102-SV_hZgvV7dnOB3iHGWL7LyhZf4AVukevErAwp48gx9s42sqvbhnpr-2CriXXU6l0kF3udcyUF_m9pfZBdaWT1mgN8PfswW3r6jI5wlVA-9GI4CDDsStZ6xpwA=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong>Vaccines Summit 2022<\/strong><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>Title:<\/strong> COVAXIN\u2122: A whole SARS-CoV-2 virion inactivated vaccine against COVID-19 <br \/><strong>Presenter:<\/strong> Robert J. Hopkins, MD, MPH &amp; TM, FACP, FIDSA, Chief Medical Officer<br \/><strong>Date:<\/strong> Wednesday, October 12, 2022 <br \/><strong>Time:<\/strong> 6:10 \u2013 6:30 p.m. ET<br \/><strong>Location:<\/strong> Sheraton Reston Hotel, Reston, VA<\/p>\n<p>\n        <strong>About Ocugen, Inc.<\/strong><br \/>\n        <br \/>Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient\u2019s lives through courageous innovation\u2014forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q8FySIYubF1w6hPrNyaQk-rthbuKeGpxRTPSEb1jbAl8b0X53yzPoj4Rnqz8Dz9-4hwIY9r-0nAMOG36lz3dSA==\" rel=\"nofollow noopener\" target=\"_blank\">www.ocugen.com<\/a>\u00a0and follow us\u00a0on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0g-LoFMGe3Cgv6o2L8NlvVy-XYse2DdDSt0MVLPSKoArUIf-MbNTfBBwKyTDdUUYb8eOHT40lqQvF9fyxjJcbg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Twitter<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lK4RSw4faaxAEorzDhcB0HVDhv3CEom1MZqG9sxkYenMaKLci-2yIe0CfB_arzo4_CMQTuHymkXYjeNwZQsd-96eWJU2nnpDUBJBZd1hgsA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>LinkedIn<\/u><\/a>. <\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/>\n        <br \/>\n        <em>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/em>\n      <\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Tiffany Hamilton<br \/>Head of Communications<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s7-7_q3yE6nyI9e8TBQeRU2xnyi5aJIfnONzpQRfZgf724wWzgJdTz86bra8dGGYfNPWtfrY4lScxyfanPNYVw==\" rel=\"nofollow noopener\" target=\"_blank\">IR@ocugen.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDJiNjU0MjktYTA4OC00MGE3LTlhOTgtNjFkYzg3MGM0M2ZkLTExOTYwNzM=\/tiny\/Ocugen.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month. \u201cI look forward to sharing more about our Modifier Gene Therapy platform\u2014a novel approach to treating inherited retinal disease\u2014during the Meeting on the Mesa, and Dr. Hopkins will provide more on COVAXIN\u2122\u2014 a whole-virion inactivated COVID-19 vaccine candidate currently in a Phase 2\/3 immuno-bridging and broadening clinical trial with the U.S. FDA\u2014at the Vaccines Summit,\u201d said Dr. Shankar Musunuri, PhD, MBA, Chairman, CEO &amp; Co-Founder of Ocugen. \u201cIt\u2019s critical that we participate in conversations about &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-692885","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month. \u201cI look forward to sharing more about our Modifier Gene Therapy platform\u2014a novel approach to treating inherited retinal disease\u2014during the Meeting on the Mesa, and Dr. Hopkins will provide more on COVAXIN\u2122\u2014 a whole-virion inactivated COVID-19 vaccine candidate currently in a Phase 2\/3 immuno-bridging and broadening clinical trial with the U.S. FDA\u2014at the Vaccines Summit,\u201d said Dr. Shankar Musunuri, PhD, MBA, Chairman, CEO &amp; Co-Founder of Ocugen. \u201cIt\u2019s critical that we participate in conversations about &hellip; Continue reading &quot;Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-06T12:33:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences\",\"datePublished\":\"2022-10-06T12:33:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/\"},\"wordCount\":535,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/\",\"name\":\"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=\",\"datePublished\":\"2022-10-06T12:33:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences - Market Newsdesk","og_description":"MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (\u201cOcugen\u201d or the \u201cCompany\u201d) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month. \u201cI look forward to sharing more about our Modifier Gene Therapy platform\u2014a novel approach to treating inherited retinal disease\u2014during the Meeting on the Mesa, and Dr. Hopkins will provide more on COVAXIN\u2122\u2014 a whole-virion inactivated COVID-19 vaccine candidate currently in a Phase 2\/3 immuno-bridging and broadening clinical trial with the U.S. FDA\u2014at the Vaccines Summit,\u201d said Dr. Shankar Musunuri, PhD, MBA, Chairman, CEO &amp; Co-Founder of Ocugen. \u201cIt\u2019s critical that we participate in conversations about &hellip; Continue reading \"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-06T12:33:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences","datePublished":"2022-10-06T12:33:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/"},"wordCount":535,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/","name":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=","datePublished":"2022-10-06T12:33:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY2MDA0OCM1MTg5NTIxIzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-inc-to-present-at-upcoming-vaccines-cell-gene-therapy-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen, Inc. to Present at Upcoming Vaccines, Cell &amp; Gene Therapy Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692885","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=692885"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/692885\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=692885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=692885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=692885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}